In the United States of America, the booster dose of the Pfizer-BioNTech Covid-19 is building up the antibody levels in the young ones of the age groups of the age 5 to 11, according to the company.
On Thursday, the company made a statement in which they mentioned that the children of age 5 to 11 had shown positive results from the Pfizer-BioNTech Covid-19 vaccine. They are raising the antibody levels.
The additional shot was given about six months after the two-dose primary series, which led to the six times increase in the antibodies against the original stain of the variant of the COVID-19 infection.
The clinical research on the booster shot included about 140 children of age 5 through 11. In a smaller sub-analysis of 3o young ones in the trial, Pfizer mentioned in the statement that the additional dose led to a 36 times increase in antibodies against the Omicron variant of the COVID-19.
Moreover, Pfizer has made an announcement via press release. But the data has not yet been made available to outside scientists for review.
According to Dr Isaac Bogoch, an infectious disease specialist at the University of Toronto, antibodies created after a booster dose of the Pfizer vaccine in adults diminish after about four months, and the same thing could occur in children.
Furthermore, protection from infection is ideal, but “based on what we know about how these vaccinations operate,” Bogoch says, “it doesn’t appear that we’re going to have a very effective campaign in doing so based on everything we know. About how these vaccines work.” Vaccines do, however, protect against more severe effects, including hospitalisation and death.
